Osteosarcoma: 25 year survival rate significantly improved with adjuvant chemotherapy
Long-term results (>25 years) of a randomized, prospective clinical trial evaluating chemotherapy in patients with high-grade, operable osteosarcomaCancer. 2012 Dec 1;118(23):5888-93
Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
59 patients who underwent treatment for stage IIA/IIB, intramedullary, high-grade osteosarcoma, between 1981 and 1984, were randomized to receive either T-10B protocol adjuvant chemotherapy or no adjuvant chemotherapy following definitive surgical resection. Improvements in disease-free survival (DFS) and overall survival (OS) were monitored over 25 years, and tumor necrosis was evaluated for impl...
Continuing Medical Education Credits
You could be earning 0.5 CME credits for each report you read.LEARN MORE